Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
it’s going to be positive Mike, I’m thinking now they’re waiting for someone else to post news about a buyout. It’s probably wishful thinking on my part though.
I guess there will be information pending after close of business today. They’re running out of bad news so that should mean good news of some type for a change.
High volume day again. Just add some news with a little meat,
High volume day on a generally low volume day. Is something cooking in the oven? That’s not a turkey?
Kind of interesting. On Dec. 23, the Department of Energy’s Loan Programs Office announced its first guarantee under Biden: $1.04 billion for Monolith Nebraska, which uses renewable electricity to split natural gas into hydrogen gas and a solid called carbon black. The hydrogen is used to produce agricultural fertilizer; the carbon black will be sold to Goodyear to make tires. Unlike most natural gas-fed hydrogen plants, the company’s proprietary process produces no carbon emissions, Monolith says, making it a clean alternative for two industries—fertilizer and rubber—that have notorious carbon footprints. It’s also the first non-nuclear project to receive support from the LPO since 2016.
It could be if it is passed and signed to law an another way to get tax credits.
From September 29, 2021 Investor Wire release posted on FuelPositive website.
FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), A 2021 Outlook and Company’s Role in the Growth of the Hydrogen Economy
The hydrogen economy is at the core of FuelPositive’s agenda. Through its carbon-free ammonia, the company offers a solution that requires 30% less energy than conventional ammonia production, with zero carbon emissions. FuelPositive can also store 65% more hydrogen in its carbon-free NH3 than traditionally highly compressed hydrogen, making hydrogen easy to store and transport using existing infrastructure, and differentiating the company from its competitors (https://ibn.fm/K63kr).
Kind of interesting. Will see if this bill passes the Senate. A ten-year tax credit worth up to $3 per kilogram of “clean hydrogen” was approved by the US House of Representatives on Friday as part of President Joe Biden’s Build Back Better Bill.
The cleaner the hydrogen produced, the higher the tax credit received by producers — a move that could make green H2 derived from renewable energy cheaper than highly polluting grey hydrogen made from unabated methane. Green hydrogen is said to cost $2.50-6/kg, compared to $1-2/kg for grey — although the latter will depend on the natural gas price. So a $3/kg subsidy on green H2 could really shake up the US hydrogen market.
The House version of the bill states that only hydrogen with lifecycle greenhouse gas emissions of less than 0.45kg of carbon dioxide equivalent (CO2e) per kilo of H2 will be eligible for the full $3 credit, which is set to begin next year.
I am happy with the roll out pace. In-house testing in March, show and tell in April Plus isn’t that when they will be taking orders? Working model in place by the middle of summer. I cannot remember but I thought it was in the winter that they will announce the location of the first deployment. They hint multiple times that they will be receiving grant money Will grant money be announced around the same time. In my opinion the unknown is the price of the unit. Also, in my opinion, a big reaction to the stock price will be if we have any orders placed before the unit is in service.
I am hoping for a few crumbs of information during the Corporate webinar on 11/18.
High volume is good
Somebody wanted shares first thing this morning
After this new hiring of employees, I do not think the company is worried about cash burn anymore. They must see revenue in the near future.
Liked that second half sales should be higher than first half
Why is this dragging out? Finally, we expect the results of the German government-sponsored and investigator-initiated REMOVE endocarditis study to be reported before the end of the year.
They will post it
A Nod's As Good As a Wink... to a Blind Horse
From Wikipedia.
B. Braun is a German medical and pharmaceutical device company, which currently has more than 63,000 employees globally, and offices and production facilities in more than 60 countries. Its headquarters are located in Melsungen, in central Germany. The company was founded in 1839 and is still owned by the Braun family.[2]
Congratulations, I thought this was all dead money but I am very happy now. But the question is, will the price fall or go up?
Re: Bsbs12 Post# 866
0,14 in Canada today.
And almost 1,000,000 shares traded. Very positive. From the website, it looks like they might even change their name.
News will be coming public as it looks like some know already,
I find this portion of the release interesting. Engagement of Marketing Services Provider The Corporation has engaged Frontier Flex Marketing (“Frontier”) to provide marketing services to the Corporation targeted at increasing investor awareness through financial media, influencer and road-show channels. Under the terms of the engagement, Frontier has been retained for a twelve-month term for an aggregate fee of $87,000 plus direct expenses. In addition,
The FDA has told Regeneron to hit the brakes on its experimental blood cancer drug trial over safety concerns.
The U.S. regulator has slapped a partial clinical hold on odronextamab, a CD20xCD3 bispecific antibody in tests for B-cell non-Hodgkin lymphoma (B-NHL), after the FDA said the company has to “further reduce the incidence of Grade 3 cytokine release syndrome (CRS),” a not uncommon safety issue in certain blood cancer trials but one that can be fatal.
This will see Regeneron pause new enrollment in the trial, allow treatment to continue for enrolled patients if they re-consent and send off a new protocol amendment to FDA, with the “goal of resuming patient enrollment in the first quarter of 2021.”
Elective surgeries will pick up once the virus slows
Maybe they’re waiting for Tesla’s battery day to make a major announcement
Were any sponsors mentioned?
ASSOCIATED PRESS
Trump expected to require American-made medical supplies, drugs to fight coronavirus outbreak
By Associated Press
Published: Mar 11, 2020 6:45 pm ET
Germany has 543 confirmed Coronavirus cases, two of which are in serious condition
FEBRUARY 26, 2020 / 05:17 PM / UPDATED 2 MINUTES AGO
Germany is at start of coronavirus epidemic - health minister
BERLIN, Feb 26 (Reuters) - Germany is at the beginning of a coronavirus epidemic after new cases sprung up which can no longer be traced to the virus’s original source in China, Health Minister Jens Spahn said on Wednesday.
He urged health ministries in Germany’s federal states as well as hospitals and employers to review their pandemic planning.
Article from Seeking Alpha: Cytosorbents latest entry in coronavirus rally; shares up 17% premarket
Jan. 28, 2020 8:06 AM ETCytosorbents Corporation (CTSO)By: Douglas W. House, SA News Editor1 Comment
Thinly traded micro cap Cytosorbents (NASDAQ:CTSO) is up 17% premarket on average volume on the heels of the publication of a report in The Lancet detailing the clinical features of patients in Wuhan, China infected with the coronavirus 2019-nCoV.
The company says levels of circulating inflammatory cytokines are correlated with the severity of illness, providing the rationale for using blood purifier CytoSorb to reduce cytokine levels and ameliorate inflammation.
Jan 28, 2020, 07:01 ET
MONMOUTH JUNCTION, N.J. , Jan. 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a critical care immunotherapy leader with more than 80,000 global treatments of its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the recent publication in The Lancet entitled, " Clinical features of patients infected with 2019 novel coronavirus in Wuhan , China ." The article notes the correlation of high levels of circulating inflammatory cytokines, or "cytokine storm," with severity of illness in patients infected with the Wuhan coronavirus (2019-nCoV). These data provide the rationale to potentially use CytoSorb, the first specifically-approved extracorporeal cytokine adsorber in the European Union, in this setting. CytoSorb is distributed in 58 countries worldwide, and is available in Hong Kong , Vietnam , Malaysia , France , and Australia where patients infected with the virus have been reported.
2 Healthcare Stocks Set to Rally into the New Year
Marty Shtrubel- January 10, 2020, 4:04 PM EDT
In a similar vein to Alimera, CytoSorbents is a beaten-down stock, displaying even further wreckage. It lost 52% of its share price during last year’s bull run.
CTSO’s blood purification technologies are used to control deadly inflammation in critically-ill and cardiac surgery patients. After exhibiting revenue growth of 51% in 2018, the growth curve slowed down to 9% year-over-year in the first three quarters of 2019.
D’Silva explained, “While the slower top-line growth could be concerning at first glance, the two primary reasons for the slowdown were related to two CS distributors and Fresenius Medical Care—which, together, accounted for ~15%-20% of the CTSO top line in 2018—entering 2019 with excess inventory, as well as CTSO running into sales-force bandwidth issues in its largest market, Germany.”
With CTSO commencing sales in Poland, Sweden, Denmark, Norway, and the Netherlands, D’Silva foresees a turnaround in the months ahead.
“While we don’t anticipate CTSO realized significant benefits from new direct sales regions in 4Q19, as most new sales hires were onboarded in 2H19, we do expect CTSO’s expanded footprint to provide a significant benefit this year… Meanwhile, We believe there are numerous clinical and regulatory catalysts are on the horizon that should be significant value drivers for the stock if successful,” said the analyst.
As a result, D’Silva kept his Buy rating and supports it with an ambitious $12 price target. Attaining this number will provide a very healthy 210% gain in the next twelve months.
Does the Street agree? Those who are taking notice certainly do. 3 Buy ratings and no Holds or Sells add up to a unanimous Strong Buy consensus rating. The recommendation comes alongside an average price target of $11 and implies upside potential of 176%.
To neutron-to keep it simple, ZNNMF ticker symbol is for US traded shares. ESU ticker is for Canadian traded shares. ESU are the official issued shares by EESTOR
IIROC Trading Halt - ESU
CNW Group CNW GroupNovember 11, 2019
VANCOUVER , Nov. 11, 2019 /CNW/ - The following issues have been halted by IIROC:
Company: EEStor Corporation
TSX-Venture Symbol: ESU (all issues)
Reason: Pending Company Contact
Halt Time (ET): 14:11
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada .
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
Halted but don’t get excited.
Look for high-volume July 1 as indexes funds that mimic the Russel 2000 will need to add CorMedix.
Scientists at Scotland's University of Strathclyde developed an experimental microelectrode device that analyzes a patient's blood and provides results as quickly as 2.5 minutes. Current testing methods for sepsis can take up to 72 hours.
This is important given that every hour without diagnosis and treatment increases the chance of dying. The research was published in the journal Biosensors and Bioelectronics.
Sepsis is caused by the overreaction of the body's immune system to an infection or injury meaning that it also starts to attack organs and tissues.
It can be treated with antibiotics if it is diagnosed early, but can lead to organ failure and death if left untreated.
About 6 million people around the world die from sepsis every year, with 52,000 of those in the UK, according to the UK Sepsis Trust.Now researchers have developed this small device that tests for interleukin-6 (IL-6), one of the biomarkers of sepsis, in the blood.
The molecule is secreted by the immune system, and many sepsis patients show increased levels of IL-6.
"At the moment, the 72-hour blood test is a very labor-intensive process but (this) type of test we envisage could be at the bedside and involve doctors or nurses being able to monitor levels of sepsis biomarkers for themselves," study author Damion Corrigan, from the department of Biomedical Engineering at Strathclyde, said in a statement.